Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
41.34
-0.92 (-2.18%)
Feb 21, 2025, 4:00 PM EST - Market closed
Revolution Medicines Revenue
Revolution Medicines had revenue of $742.00K in the twelve months ending September 30, 2024, down -97.16% year-over-year. In the year 2023, Revolution Medicines had annual revenue of $11.58M, down -67.27%.
Revenue (ttm)
$742.00K
Revenue Growth
-97.16%
P/S Ratio
10,295.75
Revenue / Employee
$1,963
Employees
378
Market Cap
7.64B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
RVMD News
- 3 days ago - Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 - GlobeNewsWire
- 24 days ago - Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewsWire
- 6 weeks ago - Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - Revolution Medicines: Risky Buy On Recent Share Price Dip - Seeking Alpha
- 2 months ago - Top 3 Health Care Stocks That Could Blast Off In December - Benzinga
- 2 months ago - Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - Revolution Medicines Announces Commencement of Public Offering of Common Stock - GlobeNewsWire